Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH ON booster immunogenicity study in healthcare workers
2022-002560-73Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Ad26.COV2.S and mRNA COVID-19 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Erasmus MC. Primary endpoints: Fold change in antibody level, Antibody levels and 2 more. Started Jul 2022; status: active.
02
Drugs
Ad26.COV2.SmRNA COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-002560-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002560-73.